Ad is loading...
FGEMX
Price
$106.34
Change
-$2.02 (-1.86%)
Updated
Nov 15 closing price
FGHMX
Price
$103.37
Change
-$1.97 (-1.87%)
Updated
Nov 15 closing price
Ad is loading...

FGEMX vs FGHMX

Header iconFGEMX vs FGHMX Comparison
Open Charts FGEMX vs FGHMXBanner chart's image
Fidelity Advisor Communication ServicesM
Price$106.34
Change-$2.02 (-1.86%)
VolumeN/A
CapitalizationN/A
Fidelity Advisor Communication ServicesC
Price$103.37
Change-$1.97 (-1.87%)
VolumeN/A
CapitalizationN/A
FGEMX vs FGHMX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FGEMX vs. FGHMX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGEMX is a Hold and FGHMX is a Hold.

FUNDAMENTALS
Fundamentals
FGEMX (1.65B) and FGHMX (1.65B) have equal amount of cash in the bank . FGEMX (0.00) and FGHMX (0.00) have matching dividends . FGEMX was incepted earlier than FGHMX: FGEMX (6 years) vs FGHMX (6 years). FGEMX (45.00) and FGHMX (45.00) have comparable annual turnover. FGEMX (0) and FGHMX (0) have matching initial minimum investment requirements. FGEMX (30.46) and FGHMX (29.73) have marching annual gain over last year. FGEMX return over 5 years is better than : 62.72 vs. FGHMX (58.98).
FGEMXFGHMXFGEMX / FGHMX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence6 years6 years-
Gain YTD23.82423.192103%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets1.65B1.65B100%
Annual Yield % from dividends0.000.00-
Returns for 1 year30.4629.73102%
Returns for 3 years10.919.22118%
Returns for 5 years62.7258.98106%
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SYK390.086.80
+1.77%
Stryker Corp
CAE21.75-0.24
-1.09%
CAE
ADTN7.75-0.22
-2.76%
ADTRAN Holdings
NUTX28.70-2.63
-8.39%
Nutex Health Inc.
RXRX6.18-0.74
-10.64%
Recursion Pharmaceuticals